JP2002504138A - ロシグリタゾンおよびインスリンを用いる糖尿病の治療 - Google Patents

ロシグリタゾンおよびインスリンを用いる糖尿病の治療

Info

Publication number
JP2002504138A
JP2002504138A JP50375799A JP50375799A JP2002504138A JP 2002504138 A JP2002504138 A JP 2002504138A JP 50375799 A JP50375799 A JP 50375799A JP 50375799 A JP50375799 A JP 50375799A JP 2002504138 A JP2002504138 A JP 2002504138A
Authority
JP
Japan
Prior art keywords
compound
insulin
diabetes
pharmaceutically acceptable
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50375799A
Other languages
English (en)
Japanese (ja)
Inventor
スミス，スティーブン・アリステア
Original Assignee
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Publication of JP2002504138A publication Critical patent/JP2002504138A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP50375799A 1997-06-18 1998-06-15 ロシグリタゾンおよびインスリンを用いる糖尿病の治療 Ceased JP2002504138A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9712866.4 1997-06-18
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
JP2002504138A true JP2002504138A (ja) 2002-02-05

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50375799A Ceased JP2002504138A (ja) 1997-06-18 1998-06-15 ロシグリタゾンおよびインスリンを用いる糖尿病の治療

Country Status (30)

Country Link
EP (1) EP0999837A1 (pt)
JP (1) JP2002504138A (pt)
KR (1) KR20010013843A (pt)
CN (1) CN1133431C (pt)
AP (1) AP1287A (pt)
AR (2) AR012997A1 (pt)
AU (1) AU8216398A (pt)
BG (1) BG104059A (pt)
BR (1) BR9810444A (pt)
CA (1) CA2294141A1 (pt)
CO (1) CO4940454A1 (pt)
DZ (1) DZ2521A1 (pt)
EA (1) EA004800B1 (pt)
GB (1) GB9712866D0 (pt)
HU (1) HUP0003260A3 (pt)
ID (1) ID23951A (pt)
IL (1) IL133143A0 (pt)
IN (1) IN189723B (pt)
MA (1) MA26511A1 (pt)
NO (1) NO996265D0 (pt)
OA (1) OA11517A (pt)
PE (1) PE104499A1 (pt)
PL (1) PL343123A1 (pt)
SK (1) SK179399A3 (pt)
TR (1) TR199903095T2 (pt)
TW (1) TW587937B (pt)
UA (1) UA70299C2 (pt)
UY (1) UY25050A1 (pt)
WO (1) WO1998057636A1 (pt)
ZA (1) ZA985237B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US6815457B1 (en) 1999-04-23 2004-11-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
KR100699614B1 (ko) * 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 퍼옥시좀 증식자 활성화된 수용체 작용제로서의 치환된4-알콕시옥사졸 유도체
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
CZ32998A3 (cs) * 1995-08-10 1998-10-14 Warner-Lambert Company Výroba léčiva pro snížení množství exogenního insulinu
EP1426048A3 (en) * 1995-09-18 2004-06-16 Ligand Pharmaceuticals, Inc. Treating hypertriglyceridemia with RXR agonists in combination with a PPARgamma agonist

Also Published As

Publication number Publication date
DZ2521A1 (fr) 2003-02-08
EA004800B1 (ru) 2004-08-26
EA200000042A1 (ru) 2000-08-28
CN1133431C (zh) 2004-01-07
IN189723B (pt) 2003-04-19
SK179399A3 (en) 2000-11-07
ID23951A (id) 2000-06-08
WO1998057636A1 (en) 1998-12-23
CO4940454A1 (es) 2000-07-24
CN1260715A (zh) 2000-07-19
AR015894A1 (es) 2001-05-30
BG104059A (en) 2000-10-31
PE104499A1 (es) 2000-01-13
UA70299C2 (en) 2004-10-15
PL343123A1 (en) 2001-07-30
GB9712866D0 (en) 1997-08-20
HUP0003260A3 (en) 2001-12-28
ZA985237B (en) 2000-02-17
IL133143A0 (en) 2001-03-19
TR199903095T2 (xx) 2000-08-21
OA11517A (en) 2004-02-04
UY25050A1 (es) 2000-09-29
HUP0003260A2 (hu) 2001-05-28
AR012997A1 (es) 2000-11-22
BR9810444A (pt) 2000-09-05
NO996265L (no) 1999-12-17
EP0999837A1 (en) 2000-05-17
NO996265D0 (no) 1999-12-17
KR20010013843A (ko) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
TW587937B (en) 2004-05-21
MA26511A1 (fr) 2004-12-20
CA2294141A1 (en) 1998-12-23
AU8216398A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
JP2002504137A (ja) チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療
JP2002504138A (ja) ロシグリタゾンおよびインスリンを用いる糖尿病の治療
JP2001510159A (ja) チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
CA2292629C (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020177612A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
JP2001523270A (ja) チアゾリジンジオンおよびスルホニルウレアを用いる糖尿病の治療
JP2001510160A (ja) チアゾリジンジオン、インスリン分泌促進薬およびアルファグルコシダーゼ阻害剤を用いる糖尿病の治療
JP2001523271A (ja) チアゾリジンジオンおよびアルファ−グルコシダーゼ阻害剤を用いる糖尿病の治療
US20020028768A1 (en) Treatment of diabetes with rosiglitazone and insulin
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CZ9904579A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012078A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040816

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20041108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041221